NEOGEN Corporation
NEOG
announced the launch of Prozap Gamma-Defense Insect Control Solution for poultry producers. The new insect control solution for poultry producers is the latest addition to the company’s Prozap product line.
The recent launch is likely to boost NEOGEN’s complete insecticide product portfolio for farm, home and ranch settings.
More on Prozap Gamma-Defense
Prozap Gamma-Defense is a micro-encapsulated, slow-release insecticide for use in and around poultry, and other livestock housing, buildings and structures. The solution will control litter beetles, flies, fleas, ticks, and other listed pests.
The highly concentrated insect control solution is formulated with gamma-cyhalothrin — the newest and most-potent pyrethroid available.
Implications of the New Insect Control Solution
Per NEOGEN’s management, the new insect control solution is proven helpful against adult and immature darkling, hide, and carrion beetles, and common pests that can have a considerable impact on poultry production. Prozap Gamma-Defense solution offers strong protection against pests, while delivering a versatile label for application and controlling problematic insects on the farm.
Image Source: Zacks Investment Research
Moreover, the versatile formula can be applied within poultry housing structures at clean out or in between flocks. It can be used as a barrier treatment outside the structure. Prozap Gamma-Defense solution can also be used on the entire footing, cracks and crevices, or banded applications.
Industry Prospects
Per a report
published in Mordor Intelligence, the insecticides market is expected to see a CAGR of 5% between 2022 and 2027. Factors such as growing demand for professional pest management products, increasing research and development activities by insecticide manufacturers, and a rising need for increased agricultural productivity due to high food demand are likely to fuel market growth.
Given the market prospects, NEOGEN’s latest addition to the insecticide product portfolio comes at an opportune time.
Other Notable Developments
In April 2022, NEOGEN launched the Prozap Protectus Pour-On Insecticide — IGR, the latest addition to its trusted Prozap insect control line. The new insect control product is a ready-to-use triple-active formula that kills chewing and sucking lice, horn flies, stable flies, and horse and deer flies. It is intended for use on beef cattle and calves.
In March 2022, NEOGEN expanded its biosecurity portfolio with the addition of the Synergize RTU — a ready-to-use formulation of the Synergize disinfectant. The new disinfectant and deodorizer eliminate the need to mix, saving users’ time and expenditure on personal protective equipment items required to handle the concentrate. The Synergize RTU is effective against Gram-negative and Gram-positive bacteria, fungi, and viruses, including those causing avian influenza and COVID-19.
Price Performance
Shares of the company have lost 41.7% in a year compared with the
industry
‘s fall of 24%.
Zacks Rank and Key Picks
NEOGEN currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are
UnitedHealth Group Incorporated
UNH
,
Medpace Holdings, Inc.
MEDP
and
Alkermes plc
ALKS
.
UnitedHealth, having a Zacks Rank #2 (Buy), reported first-quarter 2022 earnings per share (EPS) of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 14.2%. You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%.
Medpace reported first-quarter 2022 adjusted EPS of $1.69, which surpassed the Zacks Consensus Estimate by 34.1%. Revenues of $330.9 million outpaced the Zacks Consensus Estimate by 1.1%. It currently has a Zacks Rank #2.
Medpace has a historical growth rate of 27.3%. MEDP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.1%.
Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which surpassed the Zacks Consensus Estimate of a penny. Revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently carries a Zacks Rank #2.
Alkermes has an estimated long-term growth rate of 25.1%. ALKS’ earnings surpassed estimates in the trailing four quarters, the average surprise being 350.5%.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
